ClinicalTrials.gg
Active, not recruitingNCT06654466Updated Jul 16, 2026

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

An interventional study of Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale. in Hereditary Cancer Syndromes and Clinical Decision Support, sponsored by Nest Genomics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Nest Genomics · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.

Enrollment
15th of 18
100 · median 588
Started
2026
with 3 others
No phase
17 of 33
11 open now
Primary completion
2027-03
later than 3 of 18 live
Registered
24th of 33
by date

Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 24th registered.

Neoplastic Syndromes, Hereditary

47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.

Browse Neoplastic Syndromes, Hereditary studies →

Open to participants now

19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer.

The trial will also help improve the software platform (Nest). The main questions it aims to answer are:

  • Do Nest users know more about their cancer risks and recommended care than non-users?
  • Do Nest users have less psychological distress than non-users?
  • Do Nest users share cancer risks with family and other doctors more than non-users?
  • Are Nest users more likely than non-users to have up-to-date care plans?

Researchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening.

Participants will:

  • Have a genetic counseling or follow up visit
  • Take a post-visit survey
  • Intervention arm only: use the Nest Patient Navigator
  • Complete screening and follow-up care recommended by doctors
Read the detailed description

The overall objective of this project is to refine and study Nest, a software platform that integrates genetic data into patient care, with a goal of improving adherence to recommended care and empowering patients and clinicians to utilize genetic information longitudinally. Nest stores structured genetic results in the electronic medical record (EMR) and provides an interface for clinicians to order guidelines-based, personalized care plans with automated charting. For patients, the mobile friendly platform serves as a secure tool to store results, understand risks and recommended care, adhere to care, and share results with at-risk relatives. To facilitate continuity of care, patients can share genetic results and care plans with other clinicians. For this application, the investigators propose two phases. During Phase 1, the investigators will pilot the EMR-integrated Nest platform to ensure that the intervention is feasible and acceptable to clinicians and patients. Phase 2 will test Nest efficacy to improve patient and clinician experiences and outcomes, including patient knowledge of cancer risks and recommended care, and will assess implementation outcomes to facilitate future dissemination. The investigators will leverage a team with complementary expertise in genomic data, business, software development, and care of young adults with cancer risk. This team has already successfully collaborated in development of a patient-facing intervention for adolescents and young adults (AYAs) with cancer risk syndromes, and now seeks to meet the critical need for integrated and coordinated care, crossing patients, clinicians, and health systems. The long-term goal of this application is to harness an EMR integrated platform to improve care and outcomes for AYAs with cancer risk syndromes, as an initial step toward genomic data integration for an ever-increasing array of conditions with clinical implications.

Phase 1 Aims:

Aim 1: Pilot Nest among 20 young adult hereditary cancer patients and up to 20 clinicians, refining implementation to ensure feasibility and acceptability. Our working hypothesis is that the Nest intervention will be feasible and acceptable to patients and clinicians.

Phase 2 Aims:

In Phase 2, the investigators will Implement the Nest intervention by conducting a randomized trial at a single large cancer center and its associated community-based satellites.

Aim 1: Measure the impact of the Nest intervention on patient knowledge of cancer risk and recommended care, psychological distress, and information sharing with family and clinicians.

Our working hypothesis is that patients assigned to the Nest intervention will have increased knowledge of cancer risks and recommended care, without increased psychological distress, and will have increased frequency of information sharing with family and other clinicians.

Aim 2: Examine impact of the Nest intervention on clinician behavior, including guideline-concordant orders and referrals as well as EMR documentation. Our working hypothesis is that patients assigned to the Nest intervention will have higher rates of guidelines-concordant orders and referrals and Nest Clinical Decision Support (CDS) summaries in EMR documentation.

Aim 3: Evaluate implementation outcomes, including patient and clinician utilization of Nest features, to facilitate future dissemination. The investigators will examine the frequency of utilization of Nest features, including patient access and sharing of information and clinician use of orders and documentation templates, to assess features that are most useful and/or in need of further refinement.

Impact: At the completion of the proposed research, our expected outcomes are: to have a refined platform that results in increased knowledge, information sharing, and guidelines concordant care.

03

Conditions studied

  • Hereditary Cancer Syndromes
  • Clinical Decision Support

Keywords

  • Hereditary Cancer Syndromes
  • Cancer Surveillance
  • Cancer Prevention
  • Guideline Adherence
  • Clinical Decision Support
  • Adolescent and Young Adult Cancer
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-49 years, inclusive
  • previous cancer genetic testing with a finding of a pathogenic or likely pathogenic variant resulting in an increased risk of cancer warranting clinical management.
  • English-speaking and -reading
  • Receiving care at Dana Farber Cancer Institute
  • Not in active cancer therapy at the time of approach

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or >49 years
  • Has not had genetic testing for hereditary cancer syndromes or has been tested but no pathogenic or likely pathogenic variant was identified.
  • Non-English speaking and reading
  • Not receiving care at Dana Farber Cancer Institute
  • Active cancer with therapy in progress
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • No intervention
    Control Arm

    Patients in the control arm will complete a standard genetic counseling or follow-up visit and a post-visit survey.

  • Experimental
    Intervention Arm

    Patients in the intervention arm will complete a genetic counseling or follow-up visit with a clinician using Nest Clinical Decision Support and a post visit-survey. Intervention arm patients will be given access to the Nest Patient Navigator.

    Device: Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

Interventions

  • DeviceNest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

    The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.

06

What researchers measure

Primary outcomes

  1. Acceptability of Intervention Measure (AIM)

    A 4-item measure of intervention acceptability on a 5-point Likert response scale designed for a range of stakeholders. Demonstrated to be associated with intervention success.

    Time frame: within 7 days of visit

  2. Gist Comprehension of Genetic Cancer Risk

    Modified items from the Gist Comprehension of Genetic Cancer Risk (alpha=.85) ask patients their likelihood of future cancer on a 5-point Likert scale, higher score indicating greater comprehension.

    Time frame: Baseline, within 7 days of visit

  3. Knowledge of Cancer Screening

    An 11-item true-false scale (Cronbach's alpha=.81) will measure knowledge of cancer screening recommendations. Higher score indicates greater knowledge, minimum score=0, maximum score=11. Items will be modified for cancer risk syndromes under study.

    Time frame: Baseline, within 7 days of visit

  4. Psychosocial Aspects of Hereditary Cancer (PAHC)

    A 26-item questionnaire organized into six problem domains: genetics, practical issues, family, living with cancer, emotions, and children. Higher score indicates greater emotional distress. Validated in adults with hereditary cancer risk.

    Time frame: Baseline, within 7 days of visit

  5. Distress Thermometer (DT)

    A visual-analog scale from 0-"no distress" to 10-"extreme distress" to assess general psychological distress. Higher score indicates greater distress. Pairing with the PAHC enhances sensitivity and specificity.

    Time frame: Baseline, within 7 days of visit

Secondary outcomes

  1. Uncertainty of Illness Measures

    self-report - Mischel Illness Uncertainty Scale (Cronbach's α=.74-.92).5-point Likert scale ranging from "Strongly Agree" to "Strongly Disagree". Higher scores indicate greater uncertainty.

    Time frame: Baseline, within 7 days of visit

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 23, 2024
StartActual
Feb 10, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06654466
Lead sponsor
Nest Genomics
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Feb 10, 2026
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Huma Q Rana, MD
principal investigator · Dana-Farber Cancer Institute
Jennifer W Mack, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion